Please login to the form below
Aplidin
This page shows the latest Aplidin news and features for those working in and with pharma, biotech and healthcare.
PharmaMar’s cancer drug has ‘potent preclinical efficacy’ against COVID-19
Aplidin inhibits the eEF1A protein, which is associated with the SARS-CoV-2 virus, and is approved in Australia as a multiple myeloma treatment. ... According to the recently published study, in vitro Aplidin showed antiviral potency against SARS-CoV-2
Latest news
-
ViiV’s two-drug HIV combo backed by CHMP
abaloparatide) and confirming its earlier rejection of Pharma Mar’s Aplidin (plitidepsin) as a treatment for multiple myeloma.
-
Promising new agents for multiple myeloma
Other anti-cancer agents. Plitidepsin (Aplidin; PharmaMar) induces cell death through various cellular pathways.
ViiV’s two-drug HIV combo backed by CHMP
Promising new agents for multiple myeloma
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
-
Digital project manager
-
Competitive
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital strategist
-
Competitive
-
Events Executive
-
Depending on Experience
-
Digital account director
-
Competitive
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Live Webinar: Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- Another Landmark Lucid Workiversary
- Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies
- Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Onyx Health Launch Creative Studio After Record Year
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Paving the way for the HCP omnichannel experience: a guide for medical affairs
- EU approves bluebird bio’s CALD gene therapy Skysona
- Ashfield Health announces three new senior hires
PMHub
Fishawack Health
Fishawack Health is the leading global commercialization partner for the modern life science era. Established in 2001 and headquartered in...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
